{
    "clinical_study": {
        "@rank": "47055", 
        "arm_group": {
            "arm_group_label": "TG-0054 combined with G-CSF", 
            "arm_group_type": "Experimental", 
            "description": "1. G-CSF: 10 \u03bcg/kg/day, administrated via SC injections from  Day 1 to Day 8; 2. TG-0054: 3.14 mg/kg, administrated via 15-min IV infusion from Day 5 to Day 9 as needed to reach the target collection goal"
        }, 
        "brief_summary": {
            "textblock": "This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF\n      in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin\n      lymphoma or Hodgkin disease."
        }, 
        "brief_title": "PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Multiple Myeloma", 
            "Non-Hodgkin Lymphoma", 
            "Hodgkin Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 18 to 75 years of age inclusive;\n\n          -  Patients with confirmed pathology diagnosis of MM, NHL or HD;\n\n          -  Potential candidate for autologous stem cell transplantation at Investigator's\n             discretion;\n\n          -  > 4 weeks since last cycle of chemotherapy prior to the study drug administration;\n\n          -  Total dose of melphalan received \u2266 200 mg in the most recent chemotherapy treatment;\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n\n          -  Recovered from all acute toxic effects of prior chemotherapy at Investigator's\n             discretion;\n\n          -  White blood cell (WBC) count \u2267 3.0*10^9/L on screening laboratory assessments;\n\n          -  Absolute neutrophil count \u2267 1.5*10^9/L on screening laboratory assessments;\n\n          -  Platelet count \u2267 100*10^9/L on screening laboratory assessments;\n\n          -  Serum creatinine \u2266 2.2 mg/dL on screening laboratory assessments;\n\n          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin\n             < 2 x upper limit of normal (ULN) on screening laboratory assessments;\n\n          -  Negative for human immunodeficiency virus (HIV);\n\n          -  Adequate cardiac and pulmonary function to undergo leukapheresis at Investigator's\n             discretion;\n\n          -  For females, one of the following criteria must be fulfilled:\n\n               1. At least one year post-menopausal, or\n\n               2. Surgically sterile, or\n\n               3. Willing to use a double-barrier method [intrauterine device (IUD) plus condom,\n                  spermicidal gel plus condom] of contraception from study Day 1 until 28 days\n                  after the last dose of TG-0054;\n\n          -  Males must be willing to use a reliable form of contraception (use of a condom or a\n             partner fulfilling the above criteria) from study Day 1 until 28 days after the last\n             dose of TG-0054;\n\n          -  Able to provide the signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Received radiation therapy to the pelvis;\n\n          -  Received > 6 cycles of lenalidomide;\n\n          -  Evidence of bone marrow involvement of lymphoma in NHL patients;\n\n          -  Failed previous stem cell collection [failed to collect 2.0*10^6 CD34+ cells/kg\n             within 4 leukapheresis sessions after receiving granulocyte colony-stimulating factor\n             (G-CSF)];\n\n          -  Patients who have undergone previous stem cell transplantation procedure;\n\n          -  Received G-CSF within 2 weeks prior to the study drug administration;\n\n          -  History of other cancer within the past 5 years excluding MM, NHL, HD, basal cell or\n             squamous cell carcinoma of the skin;\n\n          -  History of other hematologic disorders including bleeding or thromboembolic disease\n             being treated with anti-coagulant;\n\n          -  History of poor and uncontrollable cardiovascular or pulmonary disease such as\n             myocardial infarction, cardiac arrhythmias, transient ischemic attack, stroke or\n             Chronic Obstructive Pulmonary Disease (COPD) patients hospitalized more than two\n             times a year due to underlying disease;\n\n          -  Diagnosis of sickle cell anemia or documented sickle cell trait;\n\n          -  Patients with proliferative retinopathy;\n\n          -  Uncontrollable malignancy with MM, NHL or HD, or carcinomatous meningitis, at\n             Investigator's discretion;\n\n          -  Any infection required antibiotic treatment or unexplained fever above 38 \u00b0C within 3\n             days prior to dosing;\n\n          -  Pregnant or breast-feeding;\n\n          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for\n             treatment of either a psychiatric or physical (e.g., infectious disease) illness must\n             not be enrolled into this study;\n\n          -  Received any other investigational drug within 1 month before entering the study;\n\n          -  Received prior treatment with TG-0054 but withdrew early from this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104427", 
            "org_study_id": "TG-0054-04"
        }, 
        "intervention": {
            "arm_group_label": "TG-0054 combined with G-CSF", 
            "intervention_name": "TG-0054 combined with G-CSF", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "contact": {
                "last_name": "Michael M Schuster, MD", 
                "phone": "631-444-3577"
            }, 
            "facility": {
                "address": {
                    "city": "Stony Brook", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "11794"
                }, 
                "name": "Stony Brook University Hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II, Open-Label Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease", 
        "overall_contact": {
            "last_name": "Chen-En Tsai, MD", 
            "phone": "886-2-8177-7072", 
            "phone_ext": "1211"
        }, 
        "overall_official": {
            "affiliation": "Stony Brook University Hospital", 
            "last_name": "Michael M Schuster, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Taiwan: Food and Drug Administration, Minisitry of Health and Welfare"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of all patients who collected a total number of CD34+ cells over 5.0*10^6 cells/kg within first four leukapheresis sessions", 
            "measure": "the total number of hematopoietic stem cells (HSCs) collected within first four leukapheresis sessions following treatment", 
            "safety_issue": "No", 
            "time_frame": "Day 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104427"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "the total number of HSCs collected within five leukapheresis sessions", 
                "safety_issue": "No", 
                "time_frame": "Day 5 to Day 9"
            }, 
            {
                "measure": "the average number of leukapheresis sessions required to collect \u2267 2.5*10^6 CD34+ cells/kg and \u2267 5.0*10^6 CD34+ cells /kg", 
                "safety_issue": "No", 
                "time_frame": "Day 5 to Day 9"
            }, 
            {
                "description": "incidence and severity of AE and changes in safety parameters from baseline", 
                "measure": "the safety following treatment with TG-0054 when combined with G-CSF", 
                "safety_issue": "Yes", 
                "time_frame": "one month"
            }, 
            {
                "description": "determine circulating CD34+ cell counts in peripheral blood", 
                "measure": "the pharmacodynamics (PD) following treatment with TG-0054 when combined with G-CSF", 
                "safety_issue": "No", 
                "time_frame": "Day 5 to Day 9"
            }
        ], 
        "source": "TaiGen Biotechnology Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TaiGen Biotechnology Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}